We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Romark Laboratories announced today that findings from research in the use of its drug, nitazoxanide, for the treatment of rotavirus could substantially reduce the impact of this viral disease affecting mostly children.
Israel-based drugmaker CureTech has finalized an agreement in which Teva Pharmaceutical has received an option to invest $22 million in the company, in addition to a $6 million investment announced several months ago.
GlaxoSmithKline's (GSK) Wellbutrin XL has been approved to be the first drug for treating patients with a history of seasonal affective disorder (SAD), the U.S. FDA announced.
The Scottish Medicines Consortium (SMC) has approved the Roche's Tarceva for use by patients with an advanced form of the most common type of lung cancer.
Pharmaceutical Research and Development (R&D) is slated to become the next big thing in the offshore services market in India with a growing number of multinational pharma companies seeking to establish their R&D operations in the country.
India is much-sought-after for its clinical trails capability going by the interest evinced by global companies, expressed speakers at the Bangalore Bio 2006.
As a follow-up to the March 2nd announcement, Advitech inc. today announced that the definitive agreement was signed with Cothera SAS for the French market.
Biotechnology firm Invitrogen has opened a new facility in New York which can make its Advanced Granulation Technology (AGT) media totally free of animal origin components while addressing key bottlenecks in drug production.
Barr Pharmaceuticals, Inc. today announced that its Barr Laboratories, Inc. subsidiary has entered into an agreement to settle litigation claims made by Invamed, Inc. and Apothecon, Inc., both of which have since been acquired by Sandoz, Inc., a subsidiary of Novartis AG, regarding the raw material source for Warfarin Sodium.